Furmaniak J, Sanders J, Rees Smith B
Auto Immun Highlights. 2015; 4(1):11-26.
PMID: 26000138
PMC: 4389084.
DOI: 10.1007/s13317-012-0028-1.
Kim J, Labree L, Levin L, Feldon S
Br J Ophthalmol. 2003; 88(1):72-4.
PMID: 14693778
PMC: 1771965.
DOI: 10.1136/bjo.88.1.72.
Chiovato L, Marino M, Perugi G, Fiore E, Montanelli L, Lapi P
J Endocrinol Invest. 1999; 21(11):758-64.
PMID: 9972676
DOI: 10.1007/BF03348042.
Marcocci C, Chiovato L, Mariotti S, Pinchera A
J Endocrinol Invest. 1982; 5(1):13-9.
PMID: 6896520
DOI: 10.1007/BF03350476.
Sartani A, Feigl D, Zaidel L, Ravid M
J Endocrinol Invest. 1980; 3(2):169-72.
PMID: 6893055
DOI: 10.1007/BF03348245.
Survival and tissue localization of xenogeneic human lymphocytes in hypothymic nude mice: observations in normal subjects and multiple sclerosis.
Bernard C, Mackay I
Clin Exp Immunol. 1984; 55(1):211-6.
PMID: 6692596
PMC: 1535770.
A specific IgG in Graves' ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity.
Kendall-Taylor P, Atkinson S, Holcombe M
Br Med J (Clin Res Ed). 1984; 288(6425):1183-6.
PMID: 6424781
PMC: 1441358.
DOI: 10.1136/bmj.288.6425.1183.
Thyroid-stimulating hormone (TSH) receptor antibodies and antibodies stimulating adenyl cyclase in relatives from two families with a high prevalence of Graves' hyperthyroidism: a ten-year follow-up study.
Wall J, Strakosch C, WELLBY M, Gooden J, Joyner D, Bayly R
J Clin Immunol. 1982; 2(1):15-9.
PMID: 6284789
DOI: 10.1007/BF00915973.
Anti-thyroid drugs and lymphocyte function. II. The in vivo effect on blastogenesis and suppressor cell activity in Graves' disease.
Goldrath N, Shoham J, BANK H, Eisenstein Z
Clin Exp Immunol. 1982; 50(1):62-9.
PMID: 6217001
PMC: 1536838.
Anti-thyroid drugs and lymphocyte function. I. The in vitro effect on blastogenesis and suppressor cell activity.
Goldrath N, Eisenstein Z, BANK H, Shoham J
Clin Exp Immunol. 1982; 50(1):55-61.
PMID: 6217000
PMC: 1536845.
Clinical pharmacokinetics of antithyroid drugs.
Kampmann J, Hansen J
Clin Pharmacokinet. 1981; 6(6):401-28.
PMID: 6172233
DOI: 10.2165/00003088-198106060-00001.
Antineutrophil autoantibodies in Graves' disease. Implications of thyrotropin binding to neutrophils.
Weitzman S, Stossel T, Harmon D, Daniels G, Maloof F, Ridgway E
J Clin Invest. 1985; 75(1):119-23.
PMID: 3838096
PMC: 423416.
DOI: 10.1172/JCI111663.
Palpebral asymmetry and hyperthyroidism. Two cases in connection with Graves' disease.
Uldry P, Regli F, SCAZZIGA B, Naegeli C
J Neurol. 1986; 233(2):126-7.
PMID: 3754571
DOI: 10.1007/BF00313860.
Activated T cells in Graves' disease before treatment.
Kennedy R, Di Mario U, Pozzilli P, Guy K, Leonardi M, Sensi M
Clin Exp Immunol. 1985; 59(2):377-82.
PMID: 3156702
PMC: 1577135.
Mechanism and significance of abnormal blood level of beta 2-microglobulin in patients with Graves' disease.
Han X, Yie W
J Tongji Med Univ. 1988; 8(1):35-40.
PMID: 2974088
DOI: 10.1007/BF02887775.
Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease.
Wiersinga W, Smit T, van der Gaag R, Koornneef L
J Endocrinol Invest. 1988; 11(8):615-9.
PMID: 2907524
DOI: 10.1007/BF03350193.
Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.
Romaldini J, Werner M, Rodrigues H, Teixeira V, Werner R, Farah C
J Endocrinol Invest. 1986; 9(3):233-8.
PMID: 2428860
DOI: 10.1007/BF03348107.
Progress in endocrine exophthalmos.
Havard C
Br Med J. 1979; 1(6169):1001-4.
PMID: 582020
PMC: 1598686.
DOI: 10.1136/bmj.1.6169.1001.
